Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial Brief Reports
Conclusions— We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years. These hypothesis-generating findings suggest that longer duration and more potent platelet inhibition with prasugrel may be associated with lower risk of ischemic stroke after 12 months. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00699998.
Source: Stroke - March 27, 2016 Category: Neurology Authors: Chin, C. T., Neely, B., Magnus Ohman, E., Armstrong, P. W., Corbalan, R., White, H. D., Prabhakaran, D., Winters, K. J., Fox, K. A. A., Roe, M. T., for the TRILOGY ACS Investigators Tags: Cerebrovascular Disease/Stroke, Acute Coronary Syndromes Brief Reports Source Type: research

C-Reactive Protein as a Prognostic Marker After Lacunar Stroke: Levels of Inflammatory Markers in the Treatment of Stroke Study Clinical Sciences
Conclusions— Among recent lacunar stroke patients, hsCRP levels predict the risk of recurrent strokes and other vascular events. hsCRP did not predict the response to dual antiplatelets. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.
Source: Stroke - February 24, 2014 Category: Neurology Authors: Elkind, M. S. V., Luna, J. M., McClure, L. A., Zhang, Y., Coffey, C. S., Roldan, A., Del Brutto, O. H., Pretell, E. J., Pettigrew, L. C., Meyer, B. C., Tapia, J., White, C., Benavente, O. R., on behalf of the LIMITS Investigators, The LIMITS Investigators Tags: Cerebrovascular disease/stroke, Cerebral Lacunes, Epidemiology Clinical Sciences Source Type: research

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial Clinical Sciences
Conclusions— High hsCRP levels predict recurrent stroke and poor functional outcome in acute patients with minor stroke or transient ischemic attack. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Li, J., Zhao, X., Meng, X., Lin, J., Liu, L., Wang, C., Wang, A., Wang, Y., Wang, Y., on behalf of the CHANCE Investigators Tags: Biomarkers, Inflammation, Ischemic Stroke, Transient Ischemic Attack (TIA) Clinical Sciences Source Type: research

Stress Hyperglycemia and Prognosis of Minor Ischemic Stroke and Transient Ischemic Attack Clinical Sciences
Conclusions—Stress hyperglycemia, measured by glucose/GA ratio, was associated with an increased risk of stroke in patients with a minor ischemic stroke or transient ischemic attack.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
Source: Stroke - October 23, 2017 Category: Neurology Authors: Yuesong Pan, Xueli Cai, Jing Jing, Xia Meng, Hao Li, Yongjun Wang, Xingquan Zhao, Liping Liu, David Wang, S. Claiborne Johnston, Tiemin Wei, Yilong Wang Tags: Diabetes, Type 2, Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China Brief Reports
Conclusions— CYP2C19 genotypes had significant impact on clopidogrel response and prognosis of patients with stroke. Clinical Trial Registration Information— URL: http://www.chictr.org/. Unique Identifier: ChiCTR-OCH-12002681.
Source: Stroke - May 24, 2013 Category: Neurology Authors: Jia, D.-m., Chen, Z.-b., Zhang, M.-j., Yang, W.-j., Jin, J.-l., Xia, Y.-q., Zhang, C.-l., Shao, Y., Chen, C., Xu, Y. Tags: Acute Cerebral Infarction, Genetics of Stroke Brief Reports Source Type: research

Antiplatelet Loading Improves Behavioral Outcome in a Rabbit Model of Stroke Brief Reports
Conclusions— This study suggests that usual dual antiplatelet loading is clinically beneficial in a validated model of acute stroke. Study of usual dual antiplatelet loading in acute stroke is warranted to provide treatment to stroke victims ineligible for current therapies.
Source: Stroke - October 21, 2013 Category: Neurology Authors: Meyer, D. M., Compton, P., Eastwood, J.-A., Gylys, K., Zivin, J. A. Tags: Animal models of human disease, Aggregation, Platelet function inhibitors, Emergency treatment of Stroke, Antiplatelets Brief Reports Source Type: research

Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors Clinical Sciences
Conclusions— PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel.
Source: Stroke - February 23, 2015 Category: Neurology Authors: Leonard, C. E., Bilker, W. B., Brensinger, C. M., Flockhart, D. A., Freeman, C. P., Kasner, S. E., Kimmel, S. E., Hennessy, S. Tags: Platelet function inhibitors, Acute Cerebral Infarction, Acute Stroke Syndromes, Antiplatelets, Epidemiology Clinical Sciences Source Type: research

Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone Clinical Sciences
Conclusions— Clopidogrel plus aspirin might not be superior to aspirin alone for preventing new ischemic lesion and clinical vascular events in patients with acute ischemic stroke caused by large artery atherosclerosis. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00814268.
Source: Stroke - August 21, 2016 Category: Neurology Authors: Hong, K.-S., Lee, S.-H., Kim, E. G., Cho, K.-H., Chang, D. I., Rha, J.-H., Bae, H.-J., Lee, K. B., Kim, D. E., Park, J.-M., Kim, H.-Y., Cha, J.-K., Yu, K.-H., Lee, Y.-S., Lee, S. J., Choi, J. C., Cho, Y.-J., Kwon, S. U., Kim, G.-M., Sohn, S.-I., Park, K.- Tags: Ischemic Stroke Clinical Sciences Source Type: research

Advances in our understanding of "resistance" to antiplatelet agents for prevention of ischemic stroke.
Authors: Gorelick PB, Farooq MU Abstract We review the role of aspirin and clopidogrel for prevention of ischemic stroke and explore the concept of antiplatelet therapy resistance both from a laboratory and clinical perspective and genetic polymorphisms that might influence platelet reactivity with clopidogrel administration. Debates have raged over the years about the application of platelet function tests in clinical practice. We conclude that platelet function testing is not indicated in routine clinical practice. This recommendation is supported by clinical guideline statements, a lack of a global platelet func...
Source: Stroke Research and Treatment - December 2, 2014 Category: Neurology Tags: Stroke Res Treat Source Type: research

Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack Clinical Sciences
Background and Purpose—Patients with chronic kidney disease (CKD) are at a particularly high risk for ischemic and bleeding events. Limited data exist as to the efficacy and safety of clopidogrel in stroke patients with renal dysfunction. Therefore, we sought to assess the impact of decreased kidney function on clinical outcomes for stroke patients on clopidogrel–aspirin treatment.Methods—Patients in the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) were randomized to clopidogrel–aspirin or aspirin-alone treatment. The primary efficacy outcome was new stroke during ...
Source: Stroke - October 23, 2016 Category: Neurology Authors: Zhou, Y., Pan, Y., Wu, Y., Zhao, X., Li, H., Wang, D., Johnston, S. C., Liu, L., Wang, C., Meng, X., Wang, Y., , on behalf of the CHANCE Investigators Tags: Nephrology and Kidney, Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research

Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With CYP2C19 Genetic Variants Clinical Sciences
Background and Purpose—Dysglycemia may influence the predictive value of CYP2C19 loss-of-function allele for clinical efficacy of antiplatelet drug, but the role of glycated albumin (GA) remains unclear in patients with stroke on antiplatelet drugs.Methods—The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) included 2933 patients who had GA levels and CYP2C19 genotyping. Cox proportional hazards model was used to assess the interaction between CYP2C19 loss-of-function allele (*2, *3) carrier status and the effect of antiplatelet therapy based on their GA levels.Results—...
Source: Stroke - March 27, 2017 Category: Neurology Authors: Yi Lin, Anxin Wang, Jiejie Li, Jinxi Lin, David Wang, Xia Meng, Lixian Ou, Weiqi Chen, Xingquan Zhao, Liping Liu, Yilong Wang, Yongjun Wang Tags: Biomarkers, Secondary Prevention, Genetics, Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research

Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack Stroke
Conclusions Among patients treated within 12 hours, the combination of clopidogrel and aspirin was more effective than aspirin alone in reducing the risk of recurrent ischemic stroke during the 90-day follow-up and did not increase the hemorrhagic risk. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00979589.
Source: JAHA:Journal of the American Heart Association - March 20, 2016 Category: Cardiology Authors: Li, Z., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., Meng, X., Li, H., Pan, Y., Wang, X., Wang, C., Yang, X., Zhang, C., Jing, J., Xian, Y., Johnston, S. C., Wang, Y., on behalf of the CHANCE Investigators Tags: Secondary Prevention, Ischemic Stroke, Transient Ischemic Attack (TIA) Source Type: research

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research

Does Smoking Status Influence the Effect of Clopidogrel on Secondary Stroke Prevention? (S31.005)
Conclusions:Compared to patients who never smoked, current smokers with a recent minor stroke or TIA derive a greater benefit in stroke prevention at 90 days from clopidogrel.Disclosure: Dr. Ovbiagele has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Johnston received research support from AstraZeneca. Dr. Wang has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Zhao has nothing to disclose. Dr. Wang has nothing to disclose.
Source: Neurology - February 7, 2016 Category: Neurology Authors: Ovbiagele, B., Wang, J., S. Claiborne, J., Wang, A., Wang, Y., Zhao, X., Wang, Y. Tags: Stroke Risk, Outcomes, and Complications Source Type: research